查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930156

子宫肌瘤治疗市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察，2026-2034年

Uterine Fibroid Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

子宫肌瘤治疗市场成长驱动因素

受子宫肌瘤盛行率上升和对非侵入性治疗需求增加的推动，全球子宫肌瘤治疗市场预计在预测期内将显着成长。该市场预计在2025年达到 29.7亿美元，2026年达到 33.8亿美元，到2034年将成长至 97.1亿美元，年复合成长率（CAGR）为 16.28%。北美地区凭藉其完善的医疗保健基础设施、较高的诊断率和创新疗法的日益普及，在2025年将以 45.56%的市场占有率领先。

子宫肌瘤（也称为子宫平滑肌瘤或肌瘤）是生长于子宫平滑肌和结缔组织的良性非癌性肿瘤。虽然有些病例无症状，但有症状的子宫肌瘤会引起月经出血、骨盆腔疼痛、贫血、泌尿系统併发症和不孕。久坐不动的生活方式、肥胖、停经延迟和代谢紊乱等因素导致子宫肌瘤的盛行率不断上升，推动了全球对有效药物介入的需求。

包括AbbVie Inc.、Neurocrine Biosciences、Sumitomo Pharma在内的市场主要参与者积极开发在研药物，以满足日益成长的有效子宫肌瘤治疗需求。

市场动态

市场驱动因素

子宫肌瘤负担日益加重是主要的成长因素，50岁以上女性中，70-80%患有子宫肌瘤，其中许多患者会出现严重症状。女性越来越倾向于选择保留子宫且不影响生育的药物治疗，而非手术治疗。症状患者数量的增加扩大了目标市场，并促使人们更多地采用新型疗法，例如促性腺激素释放激素促效剂、拮抗剂和选择性孕激素受体调节剂。

例如，根据NIH（2020）的资料，有症状的子宫肌瘤可导致异常子宫出血、贫血、骨盆疼痛、泌尿系统问题和不孕，这表明对医疗干预的需求日益成长。

市场限制

严重的副作用，例如骨密度下降、潮热和心血管风险，会降低患者的依从性并缩短治疗持续时间。这些安全隐患限制了长期使用，并影响医生的处方模式，尤其是在育龄妇女中。例如，在 ELARIS UF-1 和 UF-2 试验（2021年）中，约有 10%的女性因副作用而停止治疗。

市场机会

不断增加的研究计画创造丰厚的成长机会。与学术机构的合作研究、政府资助以及生物技术公司和製药公司之间的合作推动下一代疗法的开发，包括注射和新型口服 GnRH 拮抗剂。

例如，2022年5月，杜克大学的研究人员合作开发了一种微创且有效的子宫肌瘤注射疗法，拓展了治疗选择。

市场挑战

更严格的监管和安全风险对市场成长构成挑战。女性健康治疗需要长期安全性资料，尤其是在生育能力、荷尔蒙平衡和副作用方面。监管力道的加强增加了研发成本和时间，限制了中小型生物製药公司的竞争。例如，Kissei Pharmaceutical 2022年的GnRH拮抗剂Linzagolix就面临严格的审查流程。

全球市场趋势

主要市场参与者之间的策略联盟是一个显着趋势，它加速了研发进程，扩大了市场覆盖范围，并降低了研发风险。一个值得注意的合作案例是Myovant Sciences和Pfizer于2020年在北美地区成功将 Relugolix 推向市场，加快了市场准入速度，并扩大了患者的用药范围。

市场区隔分析

依药物类别

  • 到2026年，GnRH 促效剂将占据 54.18%的市场占有率，广泛用于快速缩小子宫肌瘤和抑制出血。
  • 由于研发管线的扩展和监管部门的批准，GnRH 拮抗剂预计将实现显着成长。

依类型

  • 到2026年，由于肌壁间子宫肌瘤的高发生率和严重程度，该细分市场将占据最大的市场占有率，达到 53.40%。
  • 黏膜下肌瘤预计将以 14.14%的年复合成长率成长。

依给药途径

  • 注射剂（肠外给药）凭藉其长效配方和已证实的疗效，预计到2026年将占据 72.72%的市场占有率。
  • 口服药物因其给药方便和患者依从性高而备受青睐，其年复合成长率预计为 29.5%。

依应用

  • 到2026年，缓解疗法将占据 56.42%的市场占有率，该疗法既能缓解症状又能改善疾病进程。
  • 疼痛管理疗法预计将以 14.92%的年复合成长率成长。

依通路

  • 由于覆盖面广，零售药局和药局预计在2025年将占43.1%的市场占有率。
  • 预计医院药局的年复合成长率将达到13.33%。
  • 由于电子商务平台的推广，线上药局扩张。

区域展望

北美：预计2025年市场规模将达到13.5亿美元，2026年将达到15.4亿美元，其中美国就占14.6亿美元。高发病率、先进的医疗基础设施和策略合作伙伴关係支撑了市场成长。

欧洲：预计到2026年，市场规模将达到 8.7亿美元，由于宣传活动、先进疗法和偿付政策，预计将成为成长第二快的地区。主要贡献者为英国、德国和法国。

亚太地区：预计到2026年将达到 7亿美元，其中印度占 9,000万美元，中国占 2.5亿美元。

拉丁美洲：预计到2026年将达到 1.5亿美元，主要得益于医疗保健服务的改善和公众意识的提高。

中东和非洲：GCC预计到2025年将达到 5,000万美元。

目录

第1章 引言

第2章 执行摘要

第3章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第4章 关键洞察

  • 主要国家和地区的监管环境
  • 主要公司的研发管线分析
  • 主要国家和地区的子宫肌瘤流行病学（2025年）
  • 主要产业趋势（併购、合作、新产品发表等）

第5章 全球子宫肌瘤治疗市场分析、洞察与预测（2021-2034年）

  • 市场分析、洞察与预测 - 依药物类别
    • GnRH 拮抗剂
    • GnRH 促效剂
    • 其他
  • 市场分析、洞察与预测 - 依类型
    • 肌肉注射子宫肌瘤
    • 黏膜下肌瘤
    • 其他
  • 市场分析、洞察与预测 - 依给药途径
    • 口服
    • 肠外给药
  • 市场分析、洞察与预测 - 依应用
    • 狭窄
    • 疼痛管理
    • 其他
  • 市场分析、洞察与预测 - 依通路
    • 医院药房
    • 零售药局和药局
    • 线上药房
  • 市场分析、洞察与预测 - 依地区
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第6章 北美子宫子宫肌瘤治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第7章 欧洲子宫肌瘤治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第8章 亚太地区子宫肌瘤治疗市场分析、洞察与预测（2021-2034）

  • 依国家/地区
    • 中国
    • 日本
    • 印度
    • 东南亚
    • 澳洲
    • 亚太其他地区

第9章 拉丁美洲子宫肌瘤治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第10章 中东与非洲子宫肌瘤药物市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • GCC
    • 南非
    • 中东其他地区非洲

第11章 竞争分析

  • 全球市场占有率分析（2025）
  • 公司简介
  • AbbVie Inc.
  • Sumitomo Pharma Co., Ltd.
  • Pfizer Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • ObsEva SA
  • Neurocrine Biosciences, Inc.
  • TiumBio Co., Ltd.
  • Daewon Pharmaceutical Co., Ltd.
Product Code: FBI114341

Growth Factors of uterine fibroid drugs Market

The global uterine fibroid drugs market is projected to witness significant growth during the forecast period, driven by rising prevalence of uterine fibroids and increasing demand for non-invasive therapeutic options. The market was valued at USD 2.97 billion in 2025, projected to reach USD 3.38 billion in 2026, and is expected to grow to USD 9.71 billion by 2034, exhibiting a CAGR of 16.28%. North America dominated the market in 2025 with a 45.56% share, attributed to robust healthcare infrastructure, high diagnosis rates, and increasing adoption of innovative therapies.

Uterine fibroids, also known as leiomyomas or myomas, are benign, non-cancerous growths of the uterine smooth muscle and connective tissue. While some cases remain asymptomatic, symptomatic fibroids can cause heavy menstrual bleeding, pelvic pain, anemia, urinary complications, and fertility issues. Factors such as sedentary lifestyle, obesity, delayed menopause, and metabolic disorders are contributing to the rising prevalence of uterine fibroids, boosting the global demand for effective pharmacological interventions.

Key players in the market, including AbbVie Inc., Neurocrine Biosciences, and Sumitomo Pharma, are actively developing pipeline candidates to meet the growing need for effective uterine fibroid treatments.

Market Dynamics

Market Drivers

The rising burden of uterine fibroids is the primary growth driver, affecting up to 70-80% of women by age 50, with a significant proportion experiencing severe symptoms. Women increasingly prefer uterus-preserving and fertility-friendly drug therapies over surgical options. The rising symptomatic patient population widens the addressable market, leading to increased adoption of novel therapies such as GnRH agonists, antagonists, and selective progesterone receptor modulators.

For example, according to the NIH (2020), symptomatic uterine fibroids can cause abnormal uterine bleeding, anemia, pelvic pain, urinary issues, and infertility, highlighting the growing demand for medical interventions.

Market Restraints

Severe adverse effects such as bone density loss, hot flashes, and cardiovascular risks can reduce patient adherence and limit treatment duration. These safety concerns restrict long-term usage and influence physicians' prescribing patterns, particularly for women of reproductive age. For instance, in the ELARIS UF-1 and UF-2 trials (2021), approximately 10% of women discontinued treatment due to adverse reactions.

Market Opportunities

Increasing research initiatives are creating lucrative growth opportunities. Academic collaborations, government funding, and biotech-pharma partnerships are driving the development of next-generation therapies, including injectable alternatives and novel oral GnRH antagonists.

For instance, in May 2022, researchers at Duke University collaborated to develop a minimally invasive, effective injectable therapy for uterine fibroids, expanding treatment options.

Market Challenges

Regulatory stringency and safety risks pose challenges to market growth. Women's health therapies require long-term safety data, especially regarding fertility, hormonal balance, and adverse effects. Regulatory scrutiny increases development costs and timelines, limiting smaller biopharma firms' ability to compete. For example, Kissei Pharmaceutical (2022) faced rigorous review processes for its GnRH antagonist, Linzagolix.

Global Market Trends

A prominent trend is strategic collaborations among key market players, which accelerates R&D, expands market reach, and mitigates development risks. Notable collaborations include Myovant Sciences and Pfizer (2020) for commercialization of relugolix in North America, enabling faster market access and expanded patient reach.

Segmentation Analysis

By Drug Class:

  • GnRH agonists dominated with a 54.18% share in 2026, widely adopted for rapid fibroid shrinkage and bleeding control.
  • GnRH antagonists are expected to grow significantly due to expanding pipelines and regulatory approvals.

By Type:

  • Intramural fibroids segment captured the largest share with 53.40% in 2026, due to high prevalence and symptom severity.
  • Submucosal fibroids are projected to grow at 14.14% CAGR.

By Route of Administration:

  • Parenteral (injectables) segment held 72.72% share in 2026, favored for sustained-release formulations and proven efficacy.
  • Oral drugs are growing at 29.5% CAGR, offering ease of administration and better adherence.

By Application:

  • Shrinkage segment dominated with a 56.42% share in 2026, providing both symptomatic relief and disease modification.
  • Pain management segment is projected to grow at 14.92% CAGR.

By Distribution Channel:

  • Retail pharmacies & drug stores held a 43.1% share in 2025, due to wide accessibility.
  • Hospital pharmacies are projected to grow at 13.33% CAGR.
  • Online pharmacies are expanding, driven by e-commerce platforms.

Regional Outlook

North America: Market valued at USD 1.35 billion in 2025, projected to USD 1.54 billion in 2026, with the U.S. alone reaching USD 1.46 billion. Growth is supported by high prevalence, advanced healthcare infrastructure, and strategic collaborations.

Europe: Market estimated at USD 0.87 billion in 2026, second-highest growth due to awareness programs, advanced therapies, and reimbursement policies. Major contributors include the U.K., Germany, and France.

Asia Pacific: Market projected to reach USD 0.7 billion in 2026, with India at USD 0.09 billion and China at USD 0.25 billion.

Latin America: Estimated at USD 0.15 billion in 2026, driven by improving healthcare access and awareness.

Middle East & Africa: GCC countries estimated at USD 0.05 billion in 2025.

Competitive Landscape

The market is semi-consolidated, dominated by AbbVie, Neurocrine Biosciences, Sumitomo Pharma, and Pfizer. Strategic activities include R&D investments, collaborations, and patent filings to expand their global presence. For instance, in June 2025, Altin Biosciences received a Notice of Allowance for its lead drug candidate ABC-105/ABC-205 for non-hormonal treatment of uterine fibroids. Other players include Kissei Pharmaceutical, ObsEva SA, and TiumBio.

Key Industry Developments

  • October 2025: Knight Therapeutics relaunched MYFEMBREE in Canada for heavy menstrual bleeding associated with uterine fibroids.
  • October 2025: Searchlight Pharma secured Canadian rights for Linzagolix.
  • February 2025: Kissei Pharmaceutical submitted NDA for Linzagolix in Japan.
  • December 2024: Theramex received European Commission approval for extended Yselty indication.

Conclusion

The global uterine fibroid drugs market is set to grow from USD 2.97 billion in 2025 to USD 9.71 billion by 2034, at a CAGR of 16.28%, driven by increasing prevalence, technological innovation, and expanding treatment options. North America leads due to robust healthcare infrastructure, while emerging markets offer growth potential. Strategic collaborations, R&D investments, and increasing adoption of oral and injectable therapies are expected to further enhance market growth, offering patients effective, non-surgical management of uterine fibroids worldwide.

Segmentation By Drug Class, Type, Route of Administration, Application, Distribution Channel, and Region

By Drug Class * GnRH Antagonists

  • GnRH Agonists
  • Others

By Type * Intramural Fibroid

  • Submucosal Fibroid
  • Others

By Route of Administration * Oral

  • Parenteral

By Application * Shrinkage

  • Pain Management
  • Others

By Distribution Channel * Hospital Pharmacies

  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Geography * North America (By Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Drug Class, Type, Route of Administration, Application, Distribution Channel, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regulatory Scenarios, By Key Countries/Regions
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Epidemology of Uterine Fibroids, By Key Countries/ Regions, 2025
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. GnRH Antagonists
    • 5.1.2. GnRH Agonists
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Type
    • 5.2.1. Intramural Fibroid
    • 5.2.2. Submucosal Fibroid
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Application
    • 5.4.1. Shrinkage
    • 5.4.2. Pain Management
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Retail Pharmacies & Drug Stores
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. GnRH Antagonists
    • 6.1.2. GnRH Agonists
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Type
    • 6.2.1. Intramural Fibroid
    • 6.2.2. Submucosal Fibroid
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Application
    • 6.4.1. Shrinkage
    • 6.4.2. Pain Management
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Retail Pharmacies & Drug Stores
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. GnRH Antagonists
    • 7.1.2. GnRH Agonists
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Type
    • 7.2.1. Intramural Fibroid
    • 7.2.2. Submucosal Fibroid
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Application
    • 7.4.1. Shrinkage
    • 7.4.2. Pain Management
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Retail Pharmacies & Drug Stores
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. GnRH Antagonists
    • 8.1.2. GnRH Agonists
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Type
    • 8.2.1. Intramural Fibroid
    • 8.2.2. Submucosal Fibroid
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Application
    • 8.4.1. Shrinkage
    • 8.4.2. Pain Management
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Retail Pharmacies & Drug Stores
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Southeast Asia
    • 8.6.5. Australia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. GnRH Antagonists
    • 9.1.2. GnRH Agonists
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Type
    • 9.2.1. Intramural Fibroid
    • 9.2.2. Submucosal Fibroid
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Application
    • 9.4.1. Shrinkage
    • 9.4.2. Pain Management
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Retail Pharmacies & Drug Stores
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. GnRH Antagonists
    • 10.1.2. GnRH Agonists
    • 10.1.3. Others
  • 10.2. Market Analysis, Insights and Forecast - By Type
    • 10.2.1. Intramural Fibroid
    • 10.2.2. Submucosal Fibroid
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Application
    • 10.4.1. Shrinkage
    • 10.4.2. Pain Management
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies & Drug Stores
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. AbbVie Inc.
    • 11.2.2. Sumitomo Pharma Co., Ltd.
    • 11.2.3. Pfizer Inc.
    • 11.2.4. Kissei Pharmaceutical Co., Ltd.
    • 11.2.5. ObsEva SA
    • 11.2.6. Neurocrine Biosciences, Inc.
    • 11.2.7. TiumBio Co., Ltd.
    • 11.2.8. Daewon Pharmaceutical Co., Ltd.

List of Tables

  • Table 1: Global Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Type 2021-2034
  • Table 3: Global Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Route of Adminstration 2021-2034
  • Table 4: Global Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Application, 2021-2033
  • Table 5: Global Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: Global Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 8: North America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Type 2021-2034
  • Table 09: North America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Route of Adminstration 2021-2034
  • Table 10: North America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Application, 2021-2033
  • Table 11: North America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: North America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 13: Europe Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 14: Europe Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Type 2021-2034
  • Table 15: Europe Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Route of Adminstration 2021-2034
  • Table 16: Europe Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Application, 2021-2033
  • Table 17: Europe Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Europe Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 19: Asia Pacific Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 20: Asia Pacific Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Type 2021-2034
  • Table 21: Asia Pacific Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Route of Adminstration 2021-2034
  • Table 22: Asia Pacific Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 23: Asia Pacific Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Asia Pacific Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 25: Latin America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 26: Latin America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Type 2021-2034
  • Table 27: Latin America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Route of Adminstration 2021-2034
  • Table 28: Latin America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Application, 2021-2033
  • Table 29: Latin America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Latin America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 32: Middle East & Africa Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Type 2021-2034
  • Table 33: Middle East & Africa Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Route of Adminstration 2021-2034
  • Table 34: Middle East & Africa Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 35: Middle East & Africa Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 36: Middle East & Africa Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Uterine Fibroid Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Uterine Fibroid Drugs Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Uterine Fibroid Drugs Market Value Share (%), by Type, 2025 & 2034
  • Figure 4: Global Uterine Fibroid Drugs Market Value Share (%), by Route of Administration 2025 & 2034
  • Figure 5: Global Uterine Fibroid Drugs Market Value Share (%), by Application, 2025 & 2034
  • Figure 6: Global Uterine Fibroid Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 7: Global Uterine Fibroid Drugs Market Value Share (%), by Region, 2025 & 2034
  • Figure 8: North America Uterine Fibroid Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 9: North America Uterine Fibroid Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 10: North America Uterine Fibroid Drugs Market Value (USD billion), by Type 2025 & 2034
  • Figure 11: North America Uterine Fibroid Drugs Market Value Share (%), by Type 2025
  • Figure 12: North America Uterine Fibroid Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 13: North America Uterine Fibroid Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 14: North America Uterine Fibroid Drugs Market Value (USD billion), by Application, 2025 & 2034
  • Figure 15: North America Uterine Fibroid Drugs Market Value Share (%), by Application, 2025
  • Figure 16: North America Uterine Fibroid Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 17: North America Uterine Fibroid Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 18: North America Uterine Fibroid Drugs Market Value (USD billion), by Country, 2025 & 2034
  • Figure 19: North America Uterine Fibroid Drugs Market Value Share (%), by Country, 2025
  • Figure 20: Europe Uterine Fibroid Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 21: Europe Uterine Fibroid Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 22: Europe Uterine Fibroid Drugs Market Value (USD billion), by Type 2025 & 2034
  • Figure 23: Europe Uterine Fibroid Drugs Market Value Share (%), by Type 2025
  • Figure 24: Europe Uterine Fibroid Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 25: Europe Uterine Fibroid Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 26: Europe Uterine Fibroid Drugs Market Value (USD billion), by Application, 2025 & 2034
  • Figure 27: Europe Uterine Fibroid Drugs Market Value Share (%), by Application, 2025
  • Figure 28: Europe Uterine Fibroid Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe Uterine Fibroid Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe Uterine Fibroid Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Uterine Fibroid Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Uterine Fibroid Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 33: Asia Pacific Uterine Fibroid Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 34: Asia Pacific Uterine Fibroid Drugs Market Value (USD billion), by Type 2025 & 2034
  • Figure 35: Asia Pacific Uterine Fibroid Drugs Market Value Share (%), by Type 2025
  • Figure 36: Asia Pacific Uterine Fibroid Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 37: Asia Pacific Uterine Fibroid Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 38: Asia Pacific Uterine Fibroid Drugs Market Value (USD billion), by Application, 2025 & 2034
  • Figure 39: Asia Pacific Uterine Fibroid Drugs Market Value Share (%), by Application, 2025
  • Figure 40: Asia Pacific Uterine Fibroid Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific Uterine Fibroid Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 42: Asia Pacific Uterine Fibroid Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Uterine Fibroid Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 44: Latin America Uterine Fibroid Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 45: Latin America Uterine Fibroid Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 46: Latin America Uterine Fibroid Drugs Market Value (USD billion), by Type 2025 & 2034
  • Figure 47: Latin America Uterine Fibroid Drugs Market Value Share (%), by Type 2025
  • Figure 48: Latin America Uterine Fibroid Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 49: Latin America Uterine Fibroid Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 50: Latin America Uterine Fibroid Drugs Market Value (USD billion), by Application, 2025 & 2034
  • Figure 51: Latin America Uterine Fibroid Drugs Market Value Share (%), by Application, 2025
  • Figure 52: Latin America Uterine Fibroid Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Latin America Uterine Fibroid Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Latin America Uterine Fibroid Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Uterine Fibroid Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Uterine Fibroid Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 57: Middle East & Africa Uterine Fibroid Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 58: Middle East & Africa Uterine Fibroid Drugs Market Value (USD billion), by Type 2025 & 2034
  • Figure 59: Middle East & Africa Uterine Fibroid Drugs Market Value Share (%), by Type 2025
  • Figure 60: Middle East & Africa Uterine Fibroid Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 61: Middle East & Africaa Uterine Fibroid Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 62: Middle East & Africa Uterine Fibroid Drugs Market Value (USD billion), by Application, 2025 & 2034
  • Figure 63: Middle East & Africa Uterine Fibroid Drugs Market Value Share (%), by Application, 2025
  • Figure 64: Middle East & Africa Uterine Fibroid Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa Uterine Fibroid Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa Uterine Fibroid Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Uterine Fibroid Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 68: Global Uterine Fibroid Drugs Market Share (%), by Company, 2025